Lilly's New Weight Loss Pill: Promising, but at What Cost?

Eli Lilly's new weight-loss pill, orforglipron, shows promising results in a late-stage trial, helping patients with diabetes lose nearly twenty-three pounds on average. This oral GLP-1 medication offers a convenient alternative to injectable drugs like Zepbound and Wegovy, though it comes with potential side effects like nausea and vomiting. With regulatory approval submissions on the horizon, orforglipron could soon be a new option in the fight against obesity, despite investor concerns about side effects and Lilly's current stock performance. Hosted on Acast. See acast.com/privacy for more information.